|

Trastuzumab Rezetecan Clinical Trials

4 actively recruiting trials

Pipeline

Phase 2: 4

Top Sponsors

  • Sun Yat-sen University1
  • Sheng Zhang1
  • Henan Cancer Hospital1
  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences1

Indications

  • Cancer4
  • Breast Cancer3
  • HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis1
  • Advanced Solid Tumor Cancer1
  • Urothelial Carcinoma Recurrent1

Other4 trials

Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)
Phase 2
The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis
Phase 2
Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases
Phase 2
Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.